View in EDS

Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.

Saved in:
Bibliographic Details
Title: Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
Authors: Neal JW; Division of Oncology, Stanford Cancer Institute, Palo Alto, California., Santoro A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; IRCCS Humanitas Research Hospital- Humanitas Cancer Center, Rozzano, Milan, Italy., Gonzalez-Cao M; Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain., Lim FL; Barts Health NHS Trust, St Bartholomew's Hospital, London, United Kingdom., Fang B; Astera Cancer Care, East Brunswick, New Jersey., Gentzler RD; Division of Hematology Oncology, University of Virginia Cancer Center, Charlottesville, Virginia., Goldschmidt J; Department of Medical Oncology, Blue Ridge Cancer Care, Blacksburg, Virginia., Khrizman P; MD Anderson Cancer Center at Cooper, Camden, New Jersey., Proto C; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Patel S; Division of Medical Oncology, The Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah., Puri S; Division of Medical Oncology, The Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah., Liu SV; Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia., Massarelli E; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California., Williamson D; Department of Biostatistics, Exelixis Inc, Alameda, California., Schwickart M; Department of Translational Medicine, Exelixis Inc, Alameda, California., Scheffold C; Department of Clinical Development, Exelixis Inc, Alameda, California., Andrianova S; Department of Clinical Development, Exelixis Inc, Alameda, California., Felip E; Medical Oncology Service, Vall d'Hebron Institute of Oncology (VIHO), Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Barcelona, Spain.
Source: JTO clinical and research reports [JTO Clin Res Rep] 2024 Mar 20; Vol. 5 (10), pp. 100666. Date of Electronic Publication: 2024 Mar 20 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39318387
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Neal+JW%22">Neal JW</searchLink>; Division of Oncology, Stanford Cancer Institute, Palo Alto, California.<br /><searchLink fieldCode="AU" term="%22Santoro+A%22">Santoro A</searchLink>; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; IRCCS Humanitas Research Hospital- Humanitas Cancer Center, Rozzano, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Gonzalez-Cao+M%22">Gonzalez-Cao M</searchLink>; Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Lim+FL%22">Lim FL</searchLink>; Barts Health NHS Trust, St Bartholomew's Hospital, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Fang+B%22">Fang B</searchLink>; Astera Cancer Care, East Brunswick, New Jersey.<br /><searchLink fieldCode="AU" term="%22Gentzler+RD%22">Gentzler RD</searchLink>; Division of Hematology Oncology, University of Virginia Cancer Center, Charlottesville, Virginia.<br /><searchLink fieldCode="AU" term="%22Goldschmidt+J%22">Goldschmidt J</searchLink>; Department of Medical Oncology, Blue Ridge Cancer Care, Blacksburg, Virginia.<br /><searchLink fieldCode="AU" term="%22Khrizman+P%22">Khrizman P</searchLink>; MD Anderson Cancer Center at Cooper, Camden, New Jersey.<br /><searchLink fieldCode="AU" term="%22Proto+C%22">Proto C</searchLink>; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Patel+S%22">Patel S</searchLink>; Division of Medical Oncology, The Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.<br /><searchLink fieldCode="AU" term="%22Puri+S%22">Puri S</searchLink>; Division of Medical Oncology, The Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.<br /><searchLink fieldCode="AU" term="%22Liu+SV%22">Liu SV</searchLink>; Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia.<br /><searchLink fieldCode="AU" term="%22Massarelli+E%22">Massarelli E</searchLink>; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California.<br /><searchLink fieldCode="AU" term="%22Williamson+D%22">Williamson D</searchLink>; Department of Biostatistics, Exelixis Inc, Alameda, California.<br /><searchLink fieldCode="AU" term="%22Schwickart+M%22">Schwickart M</searchLink>; Department of Translational Medicine, Exelixis Inc, Alameda, California.<br /><searchLink fieldCode="AU" term="%22Scheffold+C%22">Scheffold C</searchLink>; Department of Clinical Development, Exelixis Inc, Alameda, California.<br /><searchLink fieldCode="AU" term="%22Andrianova+S%22">Andrianova S</searchLink>; Department of Clinical Development, Exelixis Inc, Alameda, California.<br /><searchLink fieldCode="AU" term="%22Felip+E%22">Felip E</searchLink>; Medical Oncology Service, Vall d'Hebron Institute of Oncology (VIHO), Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Barcelona, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101769967%22">JTO clinical and research reports</searchLink> [JTO Clin Res Rep] 2024 Mar 20; Vol. 5 (10), pp. 100666. <i>Date of Electronic Publication: </i>2024 Mar 20 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101769967 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3643 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663643%22">26663643 </searchLink><i>NLM ISO Abbreviation: </i>JTO Clin Res Rep <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39318387
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtocrr.2024.100666
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100666
    Titles:
      – TitleFull: Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Neal JW
      – PersonEntity:
          Name:
            NameFull: Santoro A
      – PersonEntity:
          Name:
            NameFull: Gonzalez-Cao M
      – PersonEntity:
          Name:
            NameFull: Lim FL
      – PersonEntity:
          Name:
            NameFull: Fang B
      – PersonEntity:
          Name:
            NameFull: Gentzler RD
      – PersonEntity:
          Name:
            NameFull: Goldschmidt J
      – PersonEntity:
          Name:
            NameFull: Khrizman P
      – PersonEntity:
          Name:
            NameFull: Proto C
      – PersonEntity:
          Name:
            NameFull: Patel S
      – PersonEntity:
          Name:
            NameFull: Puri S
      – PersonEntity:
          Name:
            NameFull: Liu SV
      – PersonEntity:
          Name:
            NameFull: Massarelli E
      – PersonEntity:
          Name:
            NameFull: Williamson D
      – PersonEntity:
          Name:
            NameFull: Schwickart M
      – PersonEntity:
          Name:
            NameFull: Scheffold C
      – PersonEntity:
          Name:
            NameFull: Andrianova S
      – PersonEntity:
          Name:
            NameFull: Felip E
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 03
              Text: 2024 Mar 20
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3643
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: JTO clinical and research reports
              Type: main
ResultId 1